-
Product Insights
NewNet Present Value Model: Vaxart Inc’s Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine
Empower your strategies with our Net Present Value Model: Vaxart Inc's Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UBX-1325 in Diabetic Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UBX-1325 in Diabetic Macular Edema report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. UBX-1325 in Diabetic Macular Edema Drug Details: UBX-1325 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Norovirus [Strains Norwalk Gi.1 + Sydney Gii.4] (Bivalent) Vaccine in Norovirus Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Norovirus [Strains Norwalk Gi.1 + Sydney Gii.4] (Bivalent) Vaccine in Norovirus Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Norovirus [Strains Norwalk Gi.1 +...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Disitamab Vedotin in Urethral Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Disitamab Vedotin in Urethral Cancer Drug Details: Disitamab vedotin (Aidexi) is an antibody-conjugated drug that...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HIL-214 in Gastroenteritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HIL-214 in Gastroenteritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HIL-214 in GastroenteritisDrug Details:HIL-214 was under development for the prevention of acute gastroenteritis caused...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SurVaxM in Oligodendroglioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SurVaxM in Oligodendroglioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SurVaxM in OligodendrogliomaDrug Details:SurVaxM is under development for the treatment of glioblastoma, brain cancer,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Norovirus [strains GI.1 + GII.3 + GII.4 + GII.17] (tetravalent) vaccine
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Norovirus [strains GI.1 + GII.3 + GII.4 + GII.17] (tetravalent) vaccine Drug Details Vaccine...
-
Product Insights
Net Present Value Model: Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Norovirus [strains Norwalk GI.1 + Sydney...